Searched over 200M research papers
4 papers analyzed
These studies suggest that survival rates for stage 4 lung cancer are generally low, with factors like stage at diagnosis, age, and treatment differences playing significant roles in survival outcomes.
20 papers analyzed
Lung cancer survival rates significantly decrease with advancing stages at diagnosis. A study analyzing data from the National Cancer Registration Service in England found that one-year relative survival rates for lung cancer patients drop substantially with each increase in stage, with stage 4 showing the most pronounced decline. This trend is consistent across various countries, as evidenced by a population-based study comparing lung cancer survival in six developed countries. The study revealed that one-year net survival for non-small cell lung cancer (NSCLC) ranged from 30% in the UK to 46% in Sweden, with stage 4 patients experiencing the lowest survival rates.
Despite the general trend of decreasing survival with advancing stages, there are notable international differences in stage-specific survival rates. For instance, the UK and Denmark have lower survival rates compared to other countries, partly due to a more adverse stage distribution at diagnosis. However, even within the same stage, survival rates can vary significantly. For example, the net survival for TNM stage IV NSCLC is 10% lower in the UK compared to Sweden, indicating that factors beyond stage at diagnosis, such as treatment differences, also play a crucial role.
Surgical resection can impact survival outcomes for patients with multifocal NSCLC, even in advanced stages. A review of patients who underwent surgical resection for multifocal NSCLC found that those with stage IIIB or stage IV disease (determined solely based on multifocal tumors) had better survival rates than previously reported for these stages. The three-year actuarial survival for patients with T1 to T2/N0/M1 tumors was 63.6%, suggesting that complete surgical resection can offer a survival benefit in selected patients with node-negative NSCLC.
For comparison, patients with stage I NSCLC who underwent surgical resection had significantly higher survival rates. A study at the Mayo Clinic reported that 84% of stage I patients survived for two years, and 69% survived for five years. These high survival rates underscore the importance of early detection and intervention, as well as the potential benefits of surgical treatment in early-stage lung cancer.
Survival rates for stage 4 lung cancer are notably low, with significant declines observed as the disease progresses. International variations in stage-specific survival suggest that factors such as treatment differences play a crucial role. Surgical resection may offer a survival benefit for selected patients with multifocal NSCLC, even in advanced stages. Early detection and intervention remain critical for improving lung cancer outcomes.
Most relevant research papers on this topic